Lataa...
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined mechanism, leading to a reduction in cellular LDLc (LDL-cholesterol) and a concomitant increase in serum LDLc. Central to the function of PCSK9...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Portland Press Ltd.
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2669217/ https://ncbi.nlm.nih.gov/pubmed/19196236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20082407 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|